- Home
- ATXS vs SDHY Comparison
ATXS vs SDHY Comparison
Compare ATXS & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- SDHY
- Stock Information
- Founded
- ATXS 2008
- SDHY 2020
- Country
- ATXS United States
- SDHY United States
- Employees
- ATXS N/A
- SDHY N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- SDHY Finance/Investors Services
- Sector
- ATXS Health Care
- SDHY Finance
- Exchange
- ATXS Nasdaq
- SDHY Nasdaq
- Market Cap
- ATXS 401.2M
- SDHY 412.0M
- IPO Year
- ATXS 2015
- SDHY N/A
- Fundamental
- Price
- ATXS $6.65
- SDHY $16.67
- Analyst Decision
- ATXS Strong Buy
- SDHY
- Analyst Count
- ATXS 7
- SDHY 0
- Target Price
- ATXS $32.43
- SDHY N/A
- AVG Volume (30 Days)
- ATXS 304.1K
- SDHY 94.0K
- Earning Date
- ATXS 08-11-2025
- SDHY 01-01-0001
- Dividend Yield
- ATXS N/A
- SDHY 8.46%
- EPS Growth
- ATXS N/A
- SDHY N/A
- EPS
- ATXS N/A
- SDHY 1.07
- Revenue
- ATXS N/A
- SDHY N/A
- Revenue This Year
- ATXS N/A
- SDHY N/A
- Revenue Next Year
- ATXS N/A
- SDHY N/A
- P/E Ratio
- ATXS N/A
- SDHY $14.31
- Revenue Growth
- ATXS N/A
- SDHY N/A
- 52 Week Low
- ATXS $3.56
- SDHY $13.93
- 52 Week High
- ATXS $12.92
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- ATXS 60.88
- SDHY 55.80
- Support Level
- ATXS $5.94
- SDHY $16.52
- Resistance Level
- ATXS $6.49
- SDHY $16.72
- Average True Range (ATR)
- ATXS 0.34
- SDHY 0.13
- MACD
- ATXS -0.00
- SDHY -0.02
- Stochastic Oscillator
- ATXS 74.74
- SDHY 47.12
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.